Oddo BHF - Knaus Tabbert (KTA) Knaus Tabbert AG : 2024 hurt by further impact from retailers drive to cut inventories, Neutral vs Outperform

Report

Oddo BHF

Christophe Chaput

Knaus Tabbert AG : 2024 hurt by further impact from retailers' drive to cut inventories, Neutral vs Outperform

>Fresh downward revision to 2024 targets - In a press release published yesterday before market open, the Knaus Tabbert group lowered its FY 2024 targets. While it was initially anticipating € 1.3-1.4bn in FY 2024 revenues, now revenues expected to stand at the lower end of the range i.e € 1.3bn. In terms of EBITDA margin, management said it would be significantly lower than previously anticipated (previously 7-8%).In July 2024, management adopted more cautious a...

23/10/2024 1 EN

Underlying

Knaus Tabbert

See profile

DE000A2YN504 Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Christophe Chaput

Other Reports on these Companies

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - 10/23/2024

28 October could mark a crucial step forward in the resolution of the asbestos litigation. The hearing set on this date at the Delaware court could lead to the launch of the plaintiffs’ vote on the reorganisation plan (agreement if 75% of plaintiffs vote in favour of the plan). We think that this vote is highly likely to materialise, notably with the integration of J&J into the plan (hearing of 8 October). The intrinsic valuation of the group’s assets (TQC, the Beauvoir/Saint-Austell ...

1h / 12m 1h / 12m 1 EN

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - 23/10/2024

Le 28 octobre prochain pourrait marquer une avancée cruciale dans la résolution des litiges amiante. L’audience prévue pour cette date dans l’agenda du tribunal du Delaware pourrait conduire au lancement du vote des plaignants sur le plan de réorganisation (accord si 75% des plaignants votent le plan). Nous pensons que ce vote a de grandes chances d’aboutir avec l’intégration de J&J dans le plan (décision du 8 octobre dernier). La valorisation intrinsèque des actifs du groupe reviendr...

1h / 30m 1h / 30m 1 FR

Eurofins : Plus de clarifications sur la Biopharma – une réaction du marché un peu exagérée – OC ajusté à 55 € vs 58 €

>Principal point de la confcall : décryptage de la baisse de la division Biopharma - Le groupe a tenu sa conf call hier à 15h, et le titre a clôturé en baisse de 11.2%. Bien que la sanction boursière nous semble un peu sévère, elle peut être expliquée par l’accumulation de plusieurs points négatif, malgré une performance globalement satisfaisante. Voici les principaux points que nous retenons :Précisions sur la division Biopharma : la croissance en Amériques du...

31m 31m 1 FR

Sinan Doganli

Sinan Doganli

ODDO BHF Small & MIDCAP MORNING NEWS - 10/23/2024

1h / 12m 1h / 12m 1 EN

Jerôme Bodin

Jerôme Bodin

Vivendi : Q3 sales a shade below expectations, no new information on the demerger

>Outperform rating with the outlook of the demerger - Vivendi published its Q3 2024 revenues yesterday evening. The group did not hold a conference call. This publication is based on the scope of future listed entities. Q3 revenues slightly undershot our expectations, with a sharper fall in revenues for Canal+. However, there was nothing dramatic about this performance, which in our view does not represent a break in the trend. The group did not hold a conference call...

1h / 13m 1h / 13m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Knaus Tabbert AG : 2024 hurt by further impact from retailers' drive to cut inventories, Neutral vs Outperform

ODDO BHF Small & MIDCAP MORNING NEWS - 10/23/2024

ODDO BHF Small & MIDCAP MORNING NEWS - 23/10/2024

Eurofins : Plus de clarifications sur la Biopharma – une réaction du marché un peu exagérée – OC ajusté à 55 € vs 58 €

ODDO BHF Small & MIDCAP MORNING NEWS - 10/23/2024

Vivendi : Q3 sales a shade below expectations, no new information on the demerger

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe